You just read:

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

News provided by

Bayer HealthCare Pharmaceuticals Inc.

Feb 04, 2011, 02:30 ET